REG - MicroSalt PLC - Notice of AGM

MicroSaltAnnouncement

05/06/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260605:nRSE1055Ha&default-theme=true

RNS Number : 1055H  MicroSalt PLC  05 June 2026

5 June 2026

MicroSalt Plc

 

("MicroSalt" or the "Company")

Notice of AGM

 

MicroSalt (AIM: SALT), a leading manufacturer of full-flavour natural salt
with approximately 50% less sodium, announces that it will be holding its
Annual General Meeting, at the offices of Bird & Bird LLP, 12 New Fetter
Lane, London EC4A 1JP on 30 June 2026 at 11.00 a.m. (BST). The annual report
and the formal notice of the 2026 AGM will today be posted to shareholders.

 

The notice of AGM is available to review on the Company's website at:
https://microsaltinc.com/

 

For more information, please visit https://microsaltinc.com, follow on X
@MicroSaltPLC or contact:

 

 MicroSalt plc                                     Via Gracechurch Group
 Rick Guiney, CEO

 Zeus (Nominated adviser and broker)               +44 (0)20 3829 5000

 David Foreman / James Edis (Investment Banking)

 Gracechurch Group (Financial PR)                  +44 (0)20 4582 3500
 Heather Armstrong, Alexis Gore, Rebecca Scott

 

 

About MicroSalt

 

MicroSalt is disrupting the global salt market with its patented,
full-flavour, low-sodium salt designed for both food manufacturers and
consumers. Using proprietary micron-sized particles, MicroSalt delivers the
same salty taste as traditional salt with approximately 50% less sodium,
offering a scalable solution to one of the world's most pressing health
challenges. Year to date through 2025, MicroSalt has contributed to more than
634M servings made healthier.

 

Excess sodium consumption is a leading contributor to cardiovascular disease,
the world's number one cause of death. The World Health Organisation has
targeted a 30% reduction in global sodium intake by 2025, a shift projected to
save seven million lives by 2030. The economic case is equally compelling: in
the UK alone, cardiovascular disease costs £19 billion annually, and reducing
average daily salt intake by just one gram could save over 4,000 lives and
£288 million each year.

 

Operational since 2018, MicroSalt has established a defensible IP portfolio,
holding a granted US patent and 14 pending applications worldwide. These
protections create significant barriers to entry in a market expected to grow
exponentially as regulation and consumer demand accelerate.

 

MicroSalt is ideally positioned for scale and market leadership, with clear
pathways into food manufacturing, consumer channels, and ultimately the
broader £10+ billion global salt market. MicroSalt is more than a healthier
alternative-it is a disruptive, category-defining solution poised to deliver
significant commercial and societal impact.

 

For more information, please visit www.microsaltinc.co
(http://www.microsaltinc.co) or follow on X @microSaltPLC.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOAFZGGVRDRGVZM



            Copyright 2019 Regulatory News Service, all rights reserved